Review
Cell Biology
Rianne D. W. Vaes, Lizza E. L. Hendriks, Marc Vooijs, Dirk De Ruysscher
Summary: Radiation therapy can induce immunogenic cell death and release various immunogenic factors, but the search for biomarkers predicting immunogenic cell death in tumor cells remains limited. This review summarizes the available literature on potential biomarkers of radiation-induced immunogenic cell death evaluated in cancer patients and discusses their clinical relevance.
Review
Chemistry, Multidisciplinary
Sajal Sen, Miae Won, Matthew S. Levine, Yuvin Noh, Adam C. Sedgwick, Jong Seung Kim, Jonathan L. Sessler, Jonathan F. Arambula
Summary: Cancer is the second deadliest disease worldwide, and immunotherapy using immunogenic cell death (ICD) shows promise in overcoming treatment limitations. Metal-based complexes have been identified as potential ICD inducers. This review assesses the progress in this field and sets the stage for future advances.
CHEMICAL SOCIETY REVIEWS
(2022)
Article
Immunology
Tamara Polajzer, Damijan Miklavcic
Summary: Traditionally, electroporation-based therapies have used specific pulse durations for different treatments. However, recent studies have shown that pulse duration and type can be more flexible in achieving electrochemotherapy (ECT), gene electrotransfer (GET), and irreversible electroporation (IRE). The activation of the immune system in these therapies can be controlled through pulse duration, as different pulse durations and types can result in different DAMP release and immune responses.
Review
Biochemistry & Molecular Biology
Sajal Sen, Krystle Karoscik, Esther Maier, Jonathan F. Arambula
Summary: The immune system plays a vital role in maintaining homeostasis and preventing the growth of malignant cells. Immune evasion by cancer cells is a major challenge, but efforts have been made to activate the immune response through immunogenic cell death (ICD) and metal-based compounds. The development of novel ICD inducers and understanding the biological pathways associated with ICD are important for enhancing anticancer immune responses. This review provides a concise summary of these topics and discusses the early clinical evidence and future directions of ICD.
CURRENT OPINION IN CHEMICAL BIOLOGY
(2023)
Review
Chemistry, Multidisciplinary
Mingxia Jiang, Jun Zeng, Liping Zhao, Mogen Zhang, Jinlong Ma, Xiuwen Guan, Weifen Zhang
Summary: The article highlights the importance of inducing immunogenic cell death in tumor cells through chemotherapy drugs, and the promising future and potential of chemo-immunotherapy in cancer treatment.
Article
Environmental Sciences
Pei-Ju Wu, Hui-Ling Chiou, Yi-Hsien Hsieh, Chia-Liang Lin, Hsiang-Lin Lee, I-Chun Liu, Tsung-Ho Ying
Summary: Licoricidin, an active compound of Glycyrrhiza uralensis, was found to significantly inhibit cell viability and induce apoptosis in cervical cancer cells. It also triggered endoplasmic reticulum stress and upregulated the protein expression of GRP78 (Bip), CHOP, and IRE1 alpha, ultimately leading to immunogenic cell death. These findings suggest that Licoricidin may be a potential inducer of immunotherapy in advanced cervical cancer.
ENVIRONMENTAL TOXICOLOGY
(2023)
Article
Materials Science, Multidisciplinary
Jianhua Liu, Zhongmin Li, Duoyi Zhao, Xiangru Feng, Chunxi Wang, Di Li, Jianxun Ding
Summary: Nanomedicine-based chemotherapeutic formulations can induce immunogenic cell death, which enhances the effectiveness of combination chemoimmunotherapy. The combination of these formulations with immunoactivating agents is a promising strategy for clinical cancer treatment.
MATERIALS & DESIGN
(2021)
Review
Biochemistry & Molecular Biology
Tania Love Aaes, Peter Vandenabeele
Summary: Modern cancer therapies often combine cytotoxic strategies with immune activation to stimulate an antitumor response. Studying the interaction between antitumor cytotoxic therapies, cancer cells, and the immune system requires appropriate experimental tumor models. In this review, the focus is on the immunostimulatory and immunosuppressive properties of cancer cell lines used in immunogenic cell death studies.
CELL DEATH AND DIFFERENTIATION
(2021)
Review
Immunology
Claudia Galassi, Vanessa Klapp, Takahiro Yamazaki, Lorenzo Galluzzi
Summary: Cancer cells undergoing immunogenic cell death (ICD) can initiate adaptive immune responses by increasing antigenicity and adjuvanticity, and having a permissive microenvironment. Immune cell infiltration and activity in the microenvironment of dying cancer cells are essential for ICD-driven immune responses to exert cytotoxic effector functions. Different forms of radiation, including non-ionizing and ionizing radiation, can elicit ICD and enhance the immunogenicity of dying cancer cells.
IMMUNOLOGICAL REVIEWS
(2023)
Article
Cell Biology
Adriana Petrazzuolo, Maria Perez-Lanzon, Isabelle Martins, Peng Liu, Oliver Kepp, Veronique Minard-Colin, Maria Chiara Maiuri, Guido Kroemer
Summary: Immunogenic cell death (ICD) increases the immunogenicity of dying cells through a series of changes, and specific ALK inhibition may induce ICD in ALCL, stimulating the immune system and prolonging survival in cancer patients.
CELL DEATH & DISEASE
(2021)
Article
Chemistry, Multidisciplinary
Yuxiang Wang, Weiran Wang, Rong Gu, Jing Chen, Qian Chen, Tingsheng Lin, Jinhui Wu, Yiqiao Hu, Ahu Yuan
Summary: In situ vaccination using mitochondria-targeting modified fenofibric acid can induce immunogenic cell death. This treatment inhibits respiratory complex I, generates mitochondrial ROS, and triggers endoplasmic reticulum stress, leading to calreticulin exposure on tumor cellular membranes. It also promotes the leakage of mtDNA and subsequent IFN-I secretion. This approach enhances tumor antigen uptake, dendritic cell maturation, and CD8(+) T cell priming.
Article
Immunology
Adrian Eek Mariampillai, Sissel Hauge, Karoline Kongsrud, Randi G. Syljuasen
Summary: ATR inhibitors can enhance the expression of immunogenic cell death (ICD) markers in irradiated cancer cells, while caspase activation regulates this response.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Guido Kroemer, Claudia Galassi, Laurence Zitvogel, Lorenzo Galluzzi
Summary: Immunogenic cell death (ICD) plays an important role in therapy and disease, as dying mammalian cells release signals that interact with the host to determine the immunological correlates of cellular stress and death. ICD is crucial in immunosurveillance and is related to strategies evolved by pathogens and cancer cells. Additionally, normal cell death can also initiate antigen-specific immune responses.
Article
Pharmacology & Pharmacy
Wenpan Li, Yanhao Jiang, Jianqin Lu
Summary: Tumor immunotherapy, specifically tumor immunogenic cell death (ICD), has shown great potential for cancer therapy. Nanoparticles, such as liposomes, nanostructured lipid carriers, and inorganic nanoparticles, have been widely studied as vehicles for delivering ICD inducers. This review summarizes the strategies of different nanoparticles for ICD-induced cancer immunotherapy and discusses their advantages, disadvantages, and potential solutions. It aims to provide insights into the design of effective nanoparticulate systems for the therapeutic delivery of ICD inducers, ultimately promoting the development of ICD-mediated cancer immunotherapy.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Review
Cell Biology
Michal Kielbik, Izabela Szulc-Kielbik, Magdalena Klink
Summary: Immunogenic cell death (ICD), characterized by features of necroptosis and apoptosis, plays a crucial role in eliminating tumor cells through inducing an adaptive immune response. The focus of the research is on the involvement of CRT in ICD and its expression on ovarian cancer cells, as well as its prognostic and predictive value in ovarian cancer patients.
Article
Oncology
Takuro Matsumoto, Hirokazu Okayama, Shotaro Nakajima, Katsuharu Saito, Misato Ito, Akinao Kaneta, Yasuyuki Kanke, Hisashi Onozawa, Suguru Hayase, Shotaro Fujita, Wataru Sakamoto, Motonobu Saito, Zenichiro Seze, Tomoyuki Momma, Kosaku Mimura, Koji Kono
Summary: The study identified a set of 11 genes, including SH2D4A, that are downregulated during the adenoma-carcinoma sequence in MSS/CIN CRCs, mainly due to chromosome 8p deletions. The absence of SH2D4A was associated with poor prognosis and scarce T cell infiltration.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Misato Ito, Kosaku Mimura, Shotaro Nakajima, Katsuharu Saito, Aung Kyi Thar Min, Hirokazu Okayama, Motonobu Saito, Tomoyuki Momma, Zenichiro Saze, Mikio Ohtsuka, Toshiyuki Yamamoto, Koji Kono
Summary: In this study, down-regulated expression of HLA class I and up-regulated expression of inhibitory immune checkpoint ligands were observed in gastrointestinal tract metastasis of malignant melanoma patients during anti-PD-1 therapy. These findings provide new insights into the resistance mechanism of anti-PD-1 therapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Yuta Endo, Takafumi Watanabe, Motonobu Saito, Katsuharu Saito, Rei Suzuki, Hideki Sano, Yutaka Natori, Eisaku Sasaki, Makiko Ueda, Norihito Kamo, Shigenori Furukawa, Shu Soeda, Koji Kono, Shigehira Saji, Keiya Fujimori
Summary: This case report describes a rare case of recurrent ovarian cancer with TPM3-NTRK1 gene fusion that was not responsive to Entrectinib treatment. Immunohistochemistry showed negative expression of TRK protein, suggesting the need for immunohistochemistry confirmation prior to Entrectinib administration.
MOLECULAR AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Akinao Kaneta, Shotaro Nakajima, Hirokazu Okayama, Takuro Matsumoto, Katsuharu Saito, Tomohiro Kikuchi, Eisei Endo, Misato Ito, Kosaku Mimura, Yasuyuki Kanke, Motonobu Saito, Zenichiro Saze, Shotaro Fujita, Wataru Sakamoto, Hisashi Onozawa, Tomoyuki Momma, Shinji Ohki, Koji Kono
Summary: This study found that the activation of the cGAS-STING pathway contributes to the recruitment of CD8(+) TILs in dMMR/MSI CRC.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Surgery
Leo Yamada, Motonobu Saito, Hiroya Suzuki, Shotaro Mochizuki, Eisei Endo, Koji Kase, Misato Ito, Hiroshi Nakano, Naoto Yamauchi, Takuro Matsumoto, Akinao Kaneta, Yasuyuki Kanke, Hisashi Onozawa, Hiroyuki Hanayama, Hirokazu Okayama, Shotaro Fujita, Wataru Sakamoto, Yohei Watanabe, Suguru Hayase, Zenichiro Saze, Tomoyuki Momma, Shinji Ohki, Koji Kono
Summary: This study aims to evaluate the clinical factors, including central venous catheter (CVC) placement and thromboprophylaxis approach, as well as retrosternal space's width as a predictive factor for upper extremity deep vein thrombosis (UEDVT) in patients receiving esophagectomy. The study concludes that the presence of CVC may not affect the development of UEDVT, but the preoperative evaluation of retrosternal ratio may predict the occurrence of UEDVT.
Article
Oncology
Hidekazu Shirota, Keigo Komine, Masanobu Takahashi, Shin Takahashi, Eisaku Miyauchi, Hidetaka Niizuma, Hiroshi Tada, Muneaki Shimada, Tetsuya Niihori, Yoko Aoki, Ikuko Sugiyama, Maako Kawamura, Jun Yasuda, Shuhei Suzuki, Takeshi Iwaya, Motonobu Saito, Tsuyoshi Saito, Hiroyuki Shibata, Toru Furukawa, Chikashi Ishioka
Summary: There has been a paradigm shift in cancer chemotherapy towards personalized medicine with molecular-targeted drugs. The Molecular Tumor Board (MTB) serves as a platform that integrates clinical and molecular features for clinical decisions. This study retrospectively analyzed cases discussed at the MTB, summarizing genetic alterations and treatment recommendations. The results provide valuable insights for simplifying treatment recommendations and improving personalized medicine accuracy.
Article
Oncology
Shotaro Nakajima, Kosaku Mimura, Akinao Kaneta, Katsuharu Saito, Masanori Katagata, Hirokazu Okayama, Motonobu Saito, Zenichiro Saze, Yohei Watanabe, Hiroyuki Hanayama, Takeshi Tada, Wataru Sakamoto, Tomoyuki Momma, Hiromasa Ohira, Koji Kono
Summary: This study investigated the role of tumor cell-intrinsic cGAS-STING in radiation-mediated remodeling of the tumor microenvironment (TME) in esophageal squamous cell carcinoma (ESCC). The findings demonstrate that cGAS-STING is involved in radiation-induced activation of immune cells and recruitment of tumor-promoting M2-tumor-associated macrophages (TAMs) through IL-34. Targeting IL-34 to block M2-TAM infiltration may improve the efficacy of radiation therapy and combination therapy with immune checkpoint inhibitors in ESCC.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Misato Ito, Kosaku Mimura, Shotaro Nakajima, Hirokazu Okayama, Katsuharu Saito, Takahiro Nakajima, Tomohiro Kikuchi, Hisashi Onozawa, Shotaro Fujita, Wataru Sakamoto, Motonobu Saito, Tomoyuki Momma, Zenichiro Saze, Koji Kono
Summary: This study found that the increased infiltration of M2 tumor-associated macrophages (M2-TAMs) in the colorectal cancer (CRC) tumor microenvironment (TME) is related to resistance against oxidative stress mediated by the Nrf2-HO-1 axis. The mRNA expression levels of antioxidant-related genes in M2-TAMs were positively correlated with the M2-TAM signature. Additionally, the expression levels of Nrf2 and HO-1 were significantly increased in M2-TAMs compared to other macrophage subsets.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Takahiro Sato, Motonobu Saito, Shotaro Nakajima, Katsuharu Saito, Masanori Katagata, Satoshi Fukai, Hirokazu Okayama, Wataru Sakamoto, Zenichiro Saze, Tomoyuki Momma, Kosaku Mimura, Koji Kono
Summary: Background: The PI3K/AKT signaling pathway is frequently activated in gastric cancer (GC), but AKT inhibitors are not effective in unselected GC patients. Methods: The effect of AKT inhibitors on cell viability was evaluated in ARID1A-deficient and ARID1A knockdown GC cells, as well as in HER2-positive and HER2-negative GC. Results: AKT inhibitors decreased the viability of ARID1A-deficient cells, with a greater effect in ARID1A-deficient/HER2-negative GC cells. Conclusion: AKT inhibitors show higher therapeutic efficacy in ARID1A-deficient/HER2-negative GC cells, suggesting targeted therapy using AKT inhibitors as a potential treatment strategy.
Article
Oncology
Shotaro Nakajima, Akinao Kaneta, Hirokazu Okayama, Katsuharu Saito, Tomohiro Kikuchi, Eisei Endo, Takuro Matsumoto, Satoshi Fukai, Mei Sakuma, Takahiro Sato, Kosaku Mimura, Motonobu Saito, Zenichiro Saze, Wataru Sakamoto, Hisashi Onozawa, Tomoyuki Momma, Koji Kono
Summary: The impact of tumor cell-intrinsic cGAS-STING pathway on immune cell infiltration and clinical outcomes in pMMR/MSS CRC has not been thoroughly investigated. Our study reveals the expression pattern of cGAS-STING in tumor cells and its effect on T cell infiltrations and clinical outcomes in pMMR/MSS CRC. These findings provide novel insights and therapeutic strategies for patients with pMMR/MSS CRC.
Article
Oncology
Mei Sakuma, Kosaku Mimura, Shotaro Nakajima, Akinao Kaneta, Tomohiro Kikuchi, Azuma Nirei, Takeshi Tada, Hiroyuki Hanayama, Hirokazu Okayama, Wataru Sakamoto, Motonobu Saito, Tomoyuki Momma, Zenichiro Saze, Koji Kono
Summary: To predict the efficacy of treatments for patients with esophageal squamous cell carcinoma (ESCC), T cell subpopulations were evaluated in ESCC patients treated with chemotherapy (CT), chemoradiotherapy (CRT), and nivolumab therapy (NT). The frequencies of PD-1(+) or TIM-3(+)CD4(+) T cells were significantly higher in cStage IV patients. PD-1(+)CD4(+) and TIM-3(+)CD8(+) T-cell populations were significantly higher in patients treated with CRT but were not associated with treatment response. The frequencies of CD4(+) and CD8(+) central memory T cells (T-CM) were significantly decreased during NT, suggesting a potential biomarker for therapeutic response prediction in ESCC patients.
Article
Medicine, General & Internal
Wataru Sakamoto, Yasuyuki Kanke, Hisashi Onozawa, Hirokazu Okayama, Hisahito Endo, Shotaro Fujita, Motonobu Saito, Zenichiro Saze, Tomoyuki Momma, Koji Kono
Summary: This study retrospectively evaluated the clinical short-term outcomes of neoadjuvant chemotherapy (NAC) using capecitabin and oxaliplatin for locally advanced rectal cancer. The study found that there were no severe adverse effects pre- or perioperatively, radical resection was achieved in all cases, and no cases of progressive disease were observed.
FUKUSHIMA JOURNAL OF MEDICAL SCIENCE
(2022)
Meeting Abstract
Oncology
Junko Suga, Motonobu Saito, Shigehira Saji